Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54

European Heart Journal

Volumn 37, Issue 14, 2016, Pages 1133-1142

  Bonaca, Marc P ^a   Bhatt, Deepak L ^a   Steg, P Gabriel ^b   Storey, Robert F ^c   Cohen, Marc ^d   Im, Kyungah ^a   Oude Ophuis, Ton ^e   Budaj, Andrej ^f   Goto, Shinya ^g   López Sendón, José ^h   Diaz, Rafael ⁱ   Dalby, Anthony ^j   Van De Werf, Frans ^k   Ardissino, Diego ^l   Montalescot, Gilles ^m   Aylward, Philip ⁿ   Magnani, Giulia ^a   Jensen, Eva C ^o   Held, Peter ^o   Braunwald, Eugene ^a   Sabatine, Marc S ^a   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f GROCHOWSKI HOSPITAL   (Poland)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ ECLA   (Argentina)

^j MILPARK HOSPITAL   (South Africa)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l UNIVERSITY HOSPITAL OF PARMA   (Italy)

^m PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁿ FLINDERS MEDICAL CENTRE   (Australia)

^o ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

Antiplatelet therapy; Coronary artery disease; Ischaemic risk; P2Y12 inhibition; Platelet inhibition; Secondary prevention; Ticagrelor

Indexed keywords

PLACEBO; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE;

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADENOSINE; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84966570190     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv531     Document Type: Article

References (9)

1. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-1800.
2. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371: 2155-2166.
3. Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-Thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-444.e5.
4. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB III, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmao M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL, OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-2522.
5. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y, RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-1348.
6. Gwon HC, Hahn JY, ParkKW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, JeonDW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-513.
7. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J, Cesana BM, Giustino G, Sardella G. Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086-2097.
8. Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, Wohrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schomig A, Mehilli J, Kastrati A, Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252-1263.
9. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L, DAPT Study Investigators. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 2015;65:2211-2221.